A new twice-yearly HIV prevention injection, lenacapavir, is set to be more affordable and accessible in resource-limited countries like Nigeria, sparking mixed reactions due to skepticism and conspiracy theories, despite potential benefits in reducing HIV transmission and improving adherence.
WHO recommends offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention option, administered twice a year, to increase PrEP uptake and effectiveness. The guideline emphasizes using rapid diagnostic tests for individuals on injectable PrEP like LEN and cabotegravir, promoting flexible testing approaches to ensure access and continuation of PrEP, and highlights the need for further research, including HIV self-testing for long-acting injectable PrEP.